[go: up one dir, main page]

EA201300470A1 - Антитела - Google Patents

Антитела

Info

Publication number
EA201300470A1
EA201300470A1 EA201300470A EA201300470A EA201300470A1 EA 201300470 A1 EA201300470 A1 EA 201300470A1 EA 201300470 A EA201300470 A EA 201300470A EA 201300470 A EA201300470 A EA 201300470A EA 201300470 A1 EA201300470 A1 EA 201300470A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cdh17
antibodies
cancer
methods
nucleic acid
Prior art date
Application number
EA201300470A
Other languages
English (en)
Inventor
Джонатан Александер Терретт
Original Assignee
Оксфорд Байотерепьютикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оксфорд Байотерепьютикс Лтд. filed Critical Оксфорд Байотерепьютикс Лтд.
Publication of EA201300470A1 publication Critical patent/EA201300470A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Предлагаемая заявка обеспечивает антитела, включая изолированные моноклональные антитела, которые могут специфически связываться с CDH17 с высокой аффинностью. Также обеспечиваются молекулы нуклеиновой кислоты, кодирующие CDH17 антитела, экспрессионные векторы, хозяйские клетки и способы экспрессии CDH17 антител. Также обеспечиваются биспецифические молекулы и фармацевтические композиции, которые включают CDH17 антитела. Раскрываются способы для определения CDH17, а также способы для лечения различных видов рака, включая желудочный рак, рак поджелудочной железы, рак толстой кишки и колоректальный рак.
EA201300470A 2010-10-20 2011-10-19 Антитела EA201300470A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40509010P 2010-10-20 2010-10-20
PCT/US2011/001787 WO2012054084A2 (en) 2010-10-20 2011-10-19 Antibodies

Publications (1)

Publication Number Publication Date
EA201300470A1 true EA201300470A1 (ru) 2014-05-30

Family

ID=45975790

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300470A EA201300470A1 (ru) 2010-10-20 2011-10-19 Антитела

Country Status (15)

Country Link
US (2) US20130259878A1 (ru)
EP (1) EP2629796A4 (ru)
JP (1) JP2014502955A (ru)
KR (1) KR20130138802A (ru)
CN (1) CN103534268B (ru)
AU (1) AU2011318574B2 (ru)
BR (1) BR112013009551A2 (ru)
CA (1) CA2815041A1 (ru)
EA (1) EA201300470A1 (ru)
IL (1) IL225571A0 (ru)
MX (1) MX2013004476A (ru)
NZ (1) NZ610091A (ru)
SG (1) SG189835A1 (ru)
WO (1) WO2012054084A2 (ru)
ZA (1) ZA201302459B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2703949C1 (ru) * 2018-04-27 2019-10-22 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против кадгерина-17 человека, антигенсвязывающий фрагмент (Fab) против кадгерина-17 человека, содержащий указанные домены

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33276B1 (fr) 2009-04-20 2012-05-02 Oxford Biotherapeutics Ltd Anticorps spécifiques à la cadhérine-17
BR112015005857A2 (pt) * 2012-09-19 2017-08-08 Abbvie Biotherapeutics Inc métodos para identificação de anticorpos com imunogenicidade reduzida
AU2017206089B2 (en) * 2016-01-09 2020-04-16 Arbele Pty Ltd Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
EP3360898A1 (en) * 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
SG11202110121VA (en) * 2018-04-26 2021-10-28 Univ Pennsylvania Compositions and methods for retrieving tumor-related antibodies and antigens
CN112512575B (zh) * 2018-05-16 2024-08-06 嘉立医疗科技(广州)有限公司 双特异性抗体组合物及其使用方法
CN112334487B (zh) * 2018-05-16 2023-06-06 嘉立医疗科技(广州)有限公司 用于诊断和治疗癌症的组合物和方法
WO2023015169A1 (en) * 2021-08-02 2023-02-09 Tavotek Biotech (Suzhou) Ltd Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
WO2024100294A1 (en) 2022-11-11 2024-05-16 Ospedale San Raffaele S.R.L. Cdh17 car
WO2024163630A2 (en) * 2023-01-31 2024-08-08 Bighat Biosciences, Inc. Anti-cdh17 antibodies and use of the same
WO2024175093A1 (en) * 2023-02-23 2024-08-29 Hansoh Bio Llc Antibodies, antigen-binding fragments and methods of use
WO2024240227A1 (en) * 2023-05-24 2024-11-28 Multitude Therapeutics Inc. Antibodies and antibody-drug conjugates thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229208A1 (en) * 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
AU6155896A (en) * 1995-06-07 1996-12-30 Cytel Corporation Humanized antibodies to e-selectin
CN1763097B (zh) * 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
EP1354896B1 (en) * 2000-12-28 2010-02-10 Kyowa Hakko Kirin Co., Ltd. Monoclonal antibody directed against the human bst2 antigen
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EA010570B1 (ru) * 2002-11-07 2008-10-30 Иммьюноджен, Инк. Антитело к cd33 и способы его применения
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
JP2006089471A (ja) * 2004-08-26 2006-04-06 National Institute Of Advanced Industrial & Technology 癌の治療における抗モータリン２抗体と機能性核酸の使用
EP1868648B1 (en) * 2005-03-25 2015-04-15 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
US8535677B2 (en) * 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer
EP2275537B1 (en) * 2008-03-17 2014-12-24 Livtech Inc. Anti-human dlk-1 antibody having anti-tumor activity in vivo
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
EP2399934B1 (en) * 2009-02-20 2017-09-06 The University of Tokyo Novel monoclonal antibody, and use thereof
JP5748653B2 (ja) * 2009-04-10 2015-07-15 協和発酵キリン株式会社 抗ｔｉｍ−３抗体を用いた血液腫瘍治療法
MA33276B1 (fr) * 2009-04-20 2012-05-02 Oxford Biotherapeutics Ltd Anticorps spécifiques à la cadhérine-17

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2703949C1 (ru) * 2018-04-27 2019-10-22 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против кадгерина-17 человека, антигенсвязывающий фрагмент (Fab) против кадгерина-17 человека, содержащий указанные домены

Also Published As

Publication number Publication date
AU2011318574B2 (en) 2016-03-03
AU2011318574A1 (en) 2013-05-02
EP2629796A4 (en) 2015-01-28
BR112013009551A2 (pt) 2016-07-12
IL225571A0 (en) 2013-06-27
CA2815041A1 (en) 2012-04-26
CN103534268A (zh) 2014-01-22
WO2012054084A3 (en) 2013-10-17
NZ610091A (en) 2015-02-27
MX2013004476A (es) 2013-06-28
KR20130138802A (ko) 2013-12-19
SG189835A1 (en) 2013-06-28
US20130259878A1 (en) 2013-10-03
JP2014502955A (ja) 2014-02-06
WO2012054084A2 (en) 2012-04-26
EP2629796A2 (en) 2013-08-28
CN103534268B (zh) 2016-05-18
US20150093392A1 (en) 2015-04-02
ZA201302459B (en) 2014-01-29

Similar Documents

Publication Publication Date Title
EA201300470A1 (ru) Антитела
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA200870020A1 (ru) Человеческие моноклональные антитела против о8е
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
EA201101242A1 (ru) Полностью человеческие антитела, специфические для cadm1
EA202090956A3 (ru) Антитела к cd73 и их применения
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
EA201492101A1 (ru) Антитела против fcrn
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201492149A1 (ru) St2-антигенсвязывающие белки
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
EA201791577A1 (ru) СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
EA201201000A1 (ru) Способы лечения колоректального рака
CY1124006T1 (el) Συζευγμενα αντισωματα κατα toy ly75 για τη θεραπεια του καρκινου
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA201390744A1 (ru) Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
CY1119351T1 (el) Αντισωματα σε adp-ριβοζυλ κυκλαση 2
EA202090864A1 (ru) Моноклональное антитело к il-5r